Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004581
Status:
COMPLETED
Last Update Posted:
2009-02-20
First Post:
1999-11-02
Brief Title:
A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Randomized Open-Label Phase III Study of ABT-378Ritonavir in Combination With Nevirapine and Two Nucleoside Reverse Transcriptase Inhibitors NRTIs vs Investigator Selected Protease Inhibitors in Combination With Nevirapine and Two NRTIs in Antiretroviral-Experienced HIV-Infected Subjects
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the safety and effectiveness of 2 anti-HIV drug combinations in HIV-infected patients Both combinations will include nevirapine NVP 2 nucleoside reverse transcriptase inhibitors NRTIs and at least 1 protease inhibitor PI One combination will include a new protease inhibitor ABT-378 combined in a capsule with ritonavir RTV
Detailed Description:
Patients receive 1 of the following
1 ABT-378RTV plus NVP plus 2 NRTIs or
2 Investigator-selected PIs plus NVP plus 2 NRTIs
1 ABT-378RTV plus NVP plus 2 NRTIs or
2 Investigator-selected PIs plus NVP plus 2 NRTIs
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| M98-888 | None | None | None |